Human papillomavirus DNA methylation as a potential biomarker for cervical cancer

Megan A. Clarke, Nicolas Wentzensen, Lisa Mirabello, Arpita Ghosh, Sholom Wacholder, Ariana Harari, Attila Lorincz, Mark Schiffman, Robert D. Burk

Research output: Contribution to journalReview articlepeer-review

136 Scopus citations


Sexually transmitted carcinogenic human papillomavirus (HPV) infections are extraordinarily prevalent worldwide. However, most incident HPV infections clear within a few years, whereas a small minority persists to invasive cancer. Recent studies indicate that detection of methylated viral DNA may distinguish women with cervical intraepithelial neoplasia grade 2+ (CIN2+) from those with a carcinogenic HPV-type infection that shows no evidence of CIN2+. Several studies have reported a positive association between methylation of CpG sites in the L1 gene and CIN2+, although there are inconclusive results about methylation of CpG sites in the upstream regulatory region (URR). In this review, we summarize the current state of knowledge on HPV DNAmethylation in cervical carcinogenesis, and discuss the merits of different methods used to measureHPV DNA methylation. To follow the promising leads, we suggest future studies to validate the use of methylated carcinogenic HPV DNA as a predictive and/or diagnostic biomarker for risk of cervical cancer among HPV-positive women.

Original languageEnglish (US)
Pages (from-to)2125-2137
Number of pages13
JournalCancer Epidemiology Biomarkers and Prevention
Issue number12
StatePublished - Dec 2012

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Human papillomavirus DNA methylation as a potential biomarker for cervical cancer'. Together they form a unique fingerprint.

Cite this